secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001628280-24-012372
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma reports FY2023 net loss $101.2M; cash $115.2M; PDUFA for WHIM syndrome April 30
--------------------------------------------------------------------------------

- Net loss $19.1M Q4 and $101.2M FY2023; R&D $15.3M Q4 and $72.0M FY2023; SG&A $9.9M Q4 and $35.5M FY2023.
- Cash, equivalents, restricted cash and marketable securities of $115.2M at Dec 31, 2023; runway into 2025.
- FDA PDUFA target action date April 30, 2024 for mavorixafor in WHIM syndrome; launch preparations underway.
- Additional Phase 2 results and global Phase 3 trial initiation for chronic neutropenia expected in 1H24.
- No guidance change; projected runway excludes debt drawdowns or potential Priority Review Voucher monetization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/0001628280-24-012372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024012372/xfor-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer